42nd ANNUAL MEETING: MONTREAL, QUEBEC
The 42nd Annual CCNP Meeting will be held June 12 to 15, 2019 in Montreal, Quebec. Further information will be available in the near future.

41st ANNUAL MEETING: VANCOUVER, BRITISH COLUMBIA – JUNE 28-30, 2018
The 41st Annual CCNP Meeting was held at UBC Robson Square in beautiful Vancouver, British Columbia and was a successful meeting. Please find attached the minutes of the CCNP Business meeting.
Acknowledgments

In keeping with CMA guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs and not to individual speakers through an unrestricted educational grant.

The Canadian College of Neuropsychopharmacology appreciates the support of the following sponsors:

**SILVER LEVEL SPONSORSHIP**

![Janssen](image)
![Pfizer](image)
![Lundbeck](image)

*Innovation today, healthier tomorrows*

**SPONSOR LEVEL**

![Otsuka](image)
![Lundbeck](image)
![Allergan](image)
![Shire](image)
![BC Children's Hospital](image)
![CanniMed Therapeutics Inc.](image)

The Canadian College of Neuropsychopharmacology appreciates the ongoing support of Pfizer Canada Inc. for the Heinz Lehman, Innovations in Neuropsychopharmacology and the Young Investigator Awards.
2018 CCNP JOCK CLEGHORN PRIZE:

The 2018 CCNP Jock Cleghorn Prize for best poster presentation by a student was given out to two individuals:

Tristan Philippe, University of British Columbia (Basic Science): “Sex differences in stress habituation modulate pre- and post-synaptic 5-HT1A receptor function”


Congratulations to Tristan and Rubai!

2018 W.G. DEWHURST TRAVEL AWARDS RECIPIENTS:

Tara Delorme (McGill University): “The effect of chronic altered lighting conditions as motor coordination, cognitive functions and wheel running in aged mice”

Gabriella Mattina (McMaster University): “The association between 5-HTTLPR and obsessive-compulsive symptoms in women during the perinatal period”

Alice Morgunova (McGill University): “DCC gene network in the prefrontal cortex predicts brain volume and impulsivity in healthy children”

Jose Maria Restrepo (McGill University): “Differential effects of high and low doses of amphetamine in adolescence on dopamine and behavioral development”

Lauren Reynolds (McGill University): “Sex-specific effects of amphetamine in adolescence on DCC regulation, dopamine development, and cognitive maturation”

Faranak Vahid-Ansari (University of Ottawa): “Chronic desipramine treatment reverses anxiety and depression phenotypes in a mouse model of fluoxetine resistance”

Congratulations to the above recipients!

CCNP 2019 ELECTION:

An election will be held in the New Year for the following positions:

1 Councillor (Basic Science)
1 Councillor (Clinical)
2 Awards Committee (Basic Science)
2 Awards Committee (Clinical)

The deadline for nominations for these positions will be December 31, 2018. Please email your nominations to Dr. Ridha Joober, Chair – CCNP Nominating Committee at ridha.joober@mcgill.ca as well as to the CCNP Secretariat at rmena@ualberta.ca.
2019 CCNP MAJOR AWARDS NOTICES:

Please find attached information regarding the 2019 Major CCNP Awards notices. Deadline for the initial letter of nomination is **November 30, 2018** with all final documentation to be submitted by **December 31, 2018**. All documentation can be submitted electronically to the CCNP Secretariat at rmena@ualberta.ca.

---

**CCNP MEMBERSHIP**

We encourage each member of the CCNP to invite at least one other person in the field of neuropsychopharmacology to join our ranks. Please fill in your name as the sponsor and invite a colleague that you feel will be a valuable addition to the CCNP to submit an application for membership. This is very important since the larger the membership of the CCNP, the more representative of the field of neuropsychopharmacology research it will be. Please, therefore, consider asking all of your colleagues who are interested in research to consider joining. Those wishing to apply for CCNP membership can do so on-line at the CCNP website (http://www.ccnp.ca).

Membership dues are **$150 per year for Fellows**, and **$25 per year for both Junior Members and Retired Fellows**. Subscription to the *Journal of Psychiatry and Neuroscience*, the CCNP's official journal, is offered to the CCNP membership free of charge.

---

**2018 RATIFIED CCNP MEMBERS**

The following individuals, who applied during the past year for membership to the CCNP, had their memberships ratified at the Annual Meeting that was held in Vancouver, British Columbia:

**FELLOWS:**

**BOSSERT**, Jennifer, PhD  
Staff Scientist  
Department of Behavioral Neuroscience  
IRP/NIDA/NIH/DHHS  
251 Bayview Blvd., Suite 200  
Baltimore, Maryland USA  
21239  
Tel. (443) 740-2724  
Fax (443) 740-2827  
Email: Jennifer.bossert@nih.gov or get_hip@hotmail.com  
Sponsor: Dr. F. Leri

**BOUSMAN**, Chad, MPH, PhD  
Assistant Professor  
Department of Medical Genetics  
University of Calgary  
2500 University Drive NW, CDC 395  
Calgary, AB  
T3B 2X9  
Tel. (403) 441-8409  
Email: chad.bousman@ucalgary.ca  
Sponsor: Dr. D. Mueller
FELLOWS cont.:

**BOWIE**, Christopher, PhD
Professor
Department of Psychology
Queen’s University
62 Arch Street
Kingston, ON K7L 3N6
Email: bowiec@queensu.ca
Sponsor: Dr. M. Lepage

**LORDANOVA**, Mihaela, PhD
Assistant Professor
Department of Psychology
Concordia University
7141 Sherbrooke St. West, SP 244
Montreal, QC
Tel. (514) 848-2424
Email: mihaela.lordanova@concordia.ca
Sponsor: Dr. C. Flores

**MURRAY**, Jennifer, PhD
Assistant Professor
Department of Psychology
University of Guelph
50 Stone Road East
MacKinnon Extension
Guelph, ON N1G 2W1
Tel. (519) 824-4120 Ext. 56330
Email: jmurr@uoguelph.ca
Sponsor: Dr. F. Leri

JUNIOR MEMBERS:

**CARDOSO**, Taiane, PhD
Postdoctoral Research Fellow
Department of Psychiatry & Behavioral Neurosciences
McMaster University
100 West 5th Street, Suite G110
Hamilton, ON L8N 3K7
Email: deazvet@mcmaster.ca
Sponsor: Dr. B. Frey

**DELORME**, Tara, BSc.
Graduate Student
Department of Psychiatry
McGill University
6875 Boulevard LaSalle
Verdun, QC H4H 1R3
Tel. (438) 274-4158
Email: tcdelorme@hotmail.com or tara.delorme@mail.mcgill.ca
Sponsor: Dr. L. Srivastava

**DEMPSTER**, Kara, MD
Resident, Master of Neuroscience Candidate
Department of Psychiatry
London Health Sciences Centre
3-1850 Beaverbrook Ave.
London, ON N6H 0G7
Tel. (226) 234-2119
Email: kara.dempster@gmail.com
Sponsor: Dr. L. Palaniyappan

**GIFUNI**, Anthony, MD, MSc, FRCPC
PGY-6 Resident
Department of Psychiatry
McGill University
669 Brault St.
Verdun, QC H4H 2B3
Tel. (514) 999-6069
Email: Anthony.gifuni@gmail.com or Anthony.gifuni@mail.mcgill.ca
Sponsor: Dr. S. Karama

**MORGUNOVA**, Alice, BA
Graduate Student
IPN Department, McGill University
Psychiatry, 6875 Boulevard LaSalle
Verdun, QC H4H 1R3
Tel. (503) 554-8656
Email: alice.morgunova@mail.mcgill.ca
Sponsor: Dr. C. Flores

**OH**, Gary, BSc. Hon., MD
Medical Student
#210, 4901 South Drexel Blvd.
Chicago, IL USA 60615
Tel. (773) 526-1436
Email: gary.cs.oh@gmail.com
Sponsor: Dr. G. Baker

**PFAFFENSELLER**, Bianca, BSc, MSc, PhD
Postdoctoral Research Fellow
Department of Psychiatry & Behavioral Neurosciences
McMaster University
100 West 5th Street, Suite G116
Hamilton, ON L8N 3K7
Tel. (365) 888-5777
Email: pfaffenb@mcmaster.ca or Bianca.pfaffenseller@gmail.com
Sponsor: Dr. B. Frey
JUNIOR MEMBERS cont.:
RESTREPO, Mr. Jose Maria, MSc.
Department of Neuroscience, McGill University
Apt. A, 460 rue Abelard
Quebec, QC  H3E 1B5
Tel. (514) 298-5188
Email: jose.restrepo2@mail.mcgill.ca
Sponsor:  Dr. C. Flores
CCNP Medal

This Award was established to honour individuals for a meritorious career in, and outstanding contribution to, neuropsychopharmacology in Canada as evidenced by their activities in education, administration and/or patient care. Achievement in research is not a necessary criterion for this Award. An outstanding contribution implies achievement at the national or international level, and evidence of novel initiatives.

The Award, which does not have to be awarded each year, consists of a bronze medal engraved with the name of the recipient.

Nomination for 2019 CCNP Medal

The names of nominees should be received by Dr. Francesco Leri by November 30th, 2018. Supporting documentation must be received by December 31st, 2018. For each award, this documentation shall consist of:

1. A completed CCNP Medal checklist, signed by the nominee.
2. A two-page summary prepared by the sponsor describing the nominee’s work and its importance in furthering the field of neuropsychopharmacology.
3. The nominee’s curriculum vitae.
4. Up to 5 manuscripts or reprints considered by the sponsor to be pertinent to the nomination and which highlight the nominee’s work.
5. A brief biographical sketch of the candidate prepared by the sponsor.

Formal presentation of the Award will be made to the recipient during the Annual Meeting of the College.

Please send the name of the nominee and a short supporting letter to:

Dr. Francesco Leri
President - CCNP

*** Please send one copy of the above electronically to Dr. Leri at fleri@uoguelph.ca and one copy electronically to the CCNP Secretariat at rmena@ualberta.ca.

Deadline for receipt of initial nomination and short supporting letter is November 30, 2018.
CCNP Medal
Sponsored by the Canadian College of Neuropsychopharmacology

Checklist

_____ Two-page summary of my work and its importance to neuropsychopharmacology.

_____ Manuscripts and reprints pertinent to the nomination (maximum = 5)

_____ My CV

_____ Brief biographical sketch

_____ I agree to be nominated for the 2019 CCNP Medal.

_____ I attest to the accuracy of the information supplied in my application.

________________________________________  ________________
Signature                                      Date
<table>
<thead>
<tr>
<th>Year</th>
<th>Name(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Y.-D. Lapierre</td>
</tr>
<tr>
<td>1990</td>
<td>T. L. Sourkes</td>
</tr>
<tr>
<td>1991</td>
<td>N. P. V. Nair</td>
</tr>
<tr>
<td>1993</td>
<td>W. G. Dewhurst</td>
</tr>
<tr>
<td>1994</td>
<td>P. D. Hrdina</td>
</tr>
<tr>
<td>1995</td>
<td>D. J. McClure</td>
</tr>
<tr>
<td>1996</td>
<td>A. Villeneuve</td>
</tr>
<tr>
<td>1997</td>
<td>G. Baker</td>
</tr>
<tr>
<td>1998</td>
<td>No award given</td>
</tr>
<tr>
<td>1999</td>
<td>No award given</td>
</tr>
<tr>
<td>2000</td>
<td>A.G. Awad</td>
</tr>
<tr>
<td>2001</td>
<td>No award given</td>
</tr>
<tr>
<td>2002</td>
<td>T. Reader</td>
</tr>
<tr>
<td>2003</td>
<td>S.N. Young</td>
</tr>
<tr>
<td>2004</td>
<td>D. Addington</td>
</tr>
<tr>
<td>2005</td>
<td>No award given</td>
</tr>
<tr>
<td>2006</td>
<td>S. Kennedy</td>
</tr>
<tr>
<td>2007</td>
<td>R. Quirion</td>
</tr>
<tr>
<td>2008</td>
<td>S. Kutcher</td>
</tr>
<tr>
<td>2009</td>
<td>L. Yatham</td>
</tr>
<tr>
<td>2010</td>
<td>No award given</td>
</tr>
<tr>
<td>2011</td>
<td>M. Steiner</td>
</tr>
<tr>
<td>2012</td>
<td>A. Phillips</td>
</tr>
<tr>
<td>2013</td>
<td>L.T. Young</td>
</tr>
<tr>
<td>2014</td>
<td>No award given</td>
</tr>
<tr>
<td>2015</td>
<td>A. Malla</td>
</tr>
<tr>
<td>2016</td>
<td>No award given</td>
</tr>
<tr>
<td>2017</td>
<td>Z. Merali</td>
</tr>
<tr>
<td>2018</td>
<td>P. Boksa</td>
</tr>
</tbody>
</table>
Heinz Lehmann Award
For Outstanding Contributions to Neuropsychopharmacology
Sponsored by Pfizer Canada Inc.

The Heinz Lehmann Award is designed to recognize outstanding contributions by a single individual in the field of research in neuropsychopharmacology in Canada. The Award consists of $2,000 honorarium and a suitably engraved plaque. The Heinz Lehmann Award shall be presented annually for work done primarily in Canada by Canadian scientists, unless there is, in the view of the Awards Committee, no qualified nominee.

Eligibility shall include individuals from academic institutions, foundations, governmental, industrial and research organizations, regardless of age or sex. The decision of the Awards Committee shall be based on originality and uniqueness of approach to clinical or laboratory research that had led to new, significant neuropsychopharmacological knowledge of concepts, or to the development of new therapeutic agents for the treatment of mental diseases. This should be evidenced by contributions based either on a specific piece of research or on a large body of neuropsychopharmacological research done over a period of years. The Awardee is expected to give a lecture based on his/her research at the Annual Meeting of the CCNP, and to contribute a manuscript based on the lecture to the CCNP official journal, the Journal of Psychiatry & Neuroscience, no later than six months after the lecture.

Nomination for 2019 Heinz Lehmann Award

The names of nominees should be received by Dr. Francesco Leri by November 30th, 2018. Supporting documentation must be received by December 31st, 2018. For each award, this documentation shall consist of:

1. A completed Heinz Lehmann Award checklist, signed by the nominee.
2. A two-page summary prepared by the sponsor describing the nominee’s work and its importance in furthering the field of neuropsychopharmacology.
3. Up to 5 manuscripts or reprints considered by the sponsor to be pertinent to the nomination and which highlight the nominee’s work.
4. The nominee’s curriculum vitae.
5. A brief biographical sketch of the candidate prepared by the sponsor.

Formal presentation of the Award will be made to the recipient during the Annual Meeting of the College.

Note: The Heinz Lehmann Research Award may be given for basic research or clinical research in alternate years. The 2019 Award will be presented for basic research.

Please send the name of the nominee and a short supporting letter to:
Dr. Francesco Leri
CCNP President

*** Please send one copy of the above electronically to Dr. Leri at fleri@uoguelph.ca and one copy to the CCNP Secretariat at rmena@ualberta.ca.

Deadline for receipt of initial nomination and short supporting letter is November 30, 2018.
Heinz Lehmann Award
For Outstanding Contributions to Neuropsychopharmacology
Sponsored by Pfizer Canada Inc.

Checklist:

_____ Two-page summary of my work and its importance to neuropsychopharmacology.

_____ Manuscripts and reprints pertinent to the nomination (maximum = 5)

_____ My CV

_____ Brief biographical sketch

_____ I agree to be nominated for the 2019 Heinz Lehman Award.

_____ If I am the award recipient, I will give a lecture at the 2019 CCNP annual meeting.

_____ If I am the award recipient, I will contribute a manuscript to the CCNP journal, the Journal of Psychiatry & Neuroscience, within 6 months after the 2019 CCNP meeting.

_____ 250-word abstract for a paper that could be submitted to the Journal of Psychiatry & Neuroscience if I am awarded the prize.

_____ I attest to the accuracy of the information supplied in my application.

_____________________________     _______________________
Signature                                    Date
Previous Heinz Lehmann Award Recipients

1982  T. L. Sourkes
1983  G. M. Brown
1984  B. Belleau
1985  P. Seeman
1986  S. Lal
1987  C. Fibiger
1988  C. de Montigny
1989  A. A. Boulton
1990  S. N. Young
1991  R. Quirion
1992  P. Grof
1993  K. K. Midha
1994  R. O. Pihl
1995  A. C. Cuello
1996  R. Joffe
1997  N. Barden
1998  B. Sherwin
1999  J. Stewart
2000  M. Steiner
2001  F. Vaccarino
2002  H. Steiger
2003  T. DiPaolo
2004  G. Chouinard
2005  M. Meaney
2006  L.T. Young
2007  H. Anisman
2008  W. Honer
2009  A. Phillips
2010  P. Blier
2011  R. Tyndale; D. Weaver
2012  G. Turecki
2013  S. George/B. Rusak
2014  G. MacQueen
2015  D. van der Kooy
2016  L. Yatham
2017  P. Albert
2018  A. Evans
CCNP Innovations in Neuropsychopharmacology Research Award
For Outstanding Innovations in Neuropsychopharmacology by an Individual or Group
Sponsored by Pfizer Canada Inc.

The Innovations in Neuropsychopharmacology Research Award is designed to recognize innovative research in neuropsychopharmacology. The Award consists of $2,000 and a suitably engraved plaque. The Innovations in Neuropsychopharmacology Award shall be presented annually for work done primarily in Canada by Canadian scientists, unless there is, in view of the Awards Committee, no qualified nominee.

The decision of the Awards Committee will be based solely on the outstanding innovative nature of the work by an individual or a group as demonstrated by a single piece of research contributed over a number of years. The Awardee(s) is/are expected to give a lecture based on his/her/their research at the Annual Meeting of the CCNP, and to contribute a manuscript, based on the lecture, to the CCNP official journal, the Journal of Psychiatry & Neuroscience, not later than six months after the lecture.

Nomination for 2019 Innovations in Neuropsychopharmacology Research Award

The names of nominees should be received by Dr. Francesco Leri by November 30th, 2018. Supporting documentation must be received by December 31st, 2018. For each award, this documentation shall consist of:

1. A completed CCNP Innovations Award checklist, signed by the nominee.
2. A two-page summary prepared by the sponsor describing the nominee’s work and its importance in furthering the field of neuropsychopharmacology.
3. Up to 5 manuscripts or reprints considered by the sponsor to be pertinent to the nomination and which highlight the nominee’s work.
4. The nominee’s curriculum vitae.
5. A brief biographical sketch of the candidate prepared by the sponsor.

Formal presentation of the Award will be made to the recipient during the Annual Meeting of the College.

Note: The Innovations in Neuropsychopharmacology Research Award may be given for basic research or clinical research in alternate years. The 2019 Award will be presented for basic research.

Please send the name of the nominee and a short supporting letter to:
Dr. Francesco Leri
CCNP President

*** Please send one copy of the above electronically to Dr. Leri at fleri@uoguelph.ca and one copy to the CCNP Secretariat at rmena@ualberta.ca.

Deadline for receipt of initial nomination and short supporting letter is November 30, 2018.
Innovations in Neuropsychopharmacology Award
For Outstanding Contributions to Neuropsychopharmacology
Sponsored by Pfizer Canada Inc.

Checklist

_____ Two-page summary of my work and its importance to neuropsychopharmacology.

_____ Manuscripts and reprints pertinent to the nomination (maximum = 5)

_____ My CV

_____ Brief biographical sketch

_____ I agree to be nominated for the 2019 Innovations in Neuropsychopharmacology Award.

_____ If I am the award recipient, I will give a lecture at the 2019 CCNP annual meeting.

_____ If I am the award recipient, I will contribute a manuscript to the CCNP journal, the 
Journal of Psychiatry & Neuroscience, within 6 months after the 2019 CCNP meeting.

_____ 250-word abstract for a paper that could be submitted to the Journal of Psychiatry & Neuroscience if I am awarded the prize.

_____ I attest to the accuracy of the information supplied in my application.

__________________________________________  _______________________
Signature                             Date
<table>
<thead>
<tr>
<th>Year</th>
<th>Award Recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>C. Fibiger, A. Phillips</td>
</tr>
<tr>
<td>1997</td>
<td>J. Bradwejn</td>
</tr>
<tr>
<td>1998</td>
<td>S. Gauthier, J. Poirier, R. Quirion</td>
</tr>
<tr>
<td>1999</td>
<td>G. Baker, R. Coutts, A. Greenshaw</td>
</tr>
<tr>
<td>2000</td>
<td>M. Diksic</td>
</tr>
<tr>
<td>2001</td>
<td>H. Robertson</td>
</tr>
<tr>
<td>2002</td>
<td>S. Lal</td>
</tr>
<tr>
<td>2003</td>
<td>No award given</td>
</tr>
<tr>
<td>2004</td>
<td>P. Seeman, S. Kapur</td>
</tr>
<tr>
<td>2005</td>
<td>No award given</td>
</tr>
<tr>
<td>2006</td>
<td>R. Tyndale</td>
</tr>
<tr>
<td>2007</td>
<td>N. Barden</td>
</tr>
<tr>
<td>2008</td>
<td>G. MacQueen</td>
</tr>
<tr>
<td>2009</td>
<td>S. Josselyn</td>
</tr>
<tr>
<td>2010</td>
<td>S. Weiss</td>
</tr>
<tr>
<td>2011</td>
<td>M. Szyf</td>
</tr>
<tr>
<td>2012</td>
<td>G. Remington</td>
</tr>
<tr>
<td>2013</td>
<td>X. Zhang</td>
</tr>
<tr>
<td>2014</td>
<td>A. Lozano</td>
</tr>
<tr>
<td>2015</td>
<td>M. Leyton</td>
</tr>
<tr>
<td>2016</td>
<td>D. Mueller, G. Robertson</td>
</tr>
<tr>
<td>2017</td>
<td>Y. Wang</td>
</tr>
<tr>
<td>2018</td>
<td>No award given</td>
</tr>
</tbody>
</table>
Young Investigator Award
For Outstanding Contributions to Neuropsychopharmacology by a Young Investigator
Sponsored by Pfizer Canada Inc.

The Young Investigator Award is designed to recognize outstanding contributions in the field of research in neuropsychopharmacology by an individual young basic scientist or clinical investigator in Canada. Applications will be judged primarily on the basis of the candidate’s work as an independent investigator. The Award consists of a $2,000 honorarium and a suitably engraved plaque. The Young Investigator Award shall be presented annually for work done primarily in Canada by Canadian scientists, unless there is, in the view of the Awards Committee, no qualified nominee.

The major selection criterion is that the candidate be actively engaged in high quality neuropsychopharmacological research in Canada. There is no restriction concerning the field in which nominees have obtained their doctoral degree, but not more than ten years should have elapsed since the completion of their post-doctoral or residency training by July of the year of presentation. It is not required that the candidates be members of the College or have an academic appointment. The Awardee is expected to give a lecture based on his/her research at the Annual Meeting of the CCNP, and to contribute a manuscript based on the lecture to the CCNP official journal, the *Journal of Psychiatry & Neuroscience*, no later than six months after the lecture.

Nomination for 2019 CCNP Young Investigator Award

The names of nominees should be received by Dr. Francesco Leri by November 30th, 2018. Supporting documentation must be received by December 31st, 2018. For each award, this documentation shall consist of:

1. A completed Young Investigator Award checklist, signed by the nominee.
2. A two-page summary prepared by the sponsor describing the nominee’s work and its importance in furthering the field of neuropsychopharmacology.
3. Up to 5 manuscripts or reprints considered by the sponsor to be pertinent to the nomination and which highlight the nominee’s work.
4. The nominee’s curriculum vitae.
5. A brief biographical sketch of the candidate prepared by the sponsor.

Formal presentation of the Award will be made to the recipient during the Annual Meeting of the College

**Note:** The Young Investigator Award is given for basic research or clinical research in alternate years. The 2019 Award will be presented for clinical research.

Please send the name of the nominee and a short supporting letter to:

Dr. Francesco Leri
CCNP President

*** Please send one copy of the above electronically to Dr. Leri at fleri@uoguelph.ca and one copy to the CCNP Secretariat at rmena@ualberta.ca.

**Deadline for receipt of initial nomination and short supporting letter is November 30, 2018.**
Young Investigator Award
For Outstanding Contributions to Neuropsychopharmacology
Sponsored by Pfizer Canada Inc.

Checklist

_____ Two-page summary of my work and its importance to neuropsychopharmacology.

_____ Manuscripts and reprints pertinent to the nomination (maximum = 5)

_____ My CV

_____ Brief biographical sketch

_____ I agree to be nominated for the 2019 Young Investigator Award.

_____ If I am the award recipient, I will give a lecture at the 2019 CCNP annual meeting.

_____ If I am the award recipient, I will contribute a manuscript to the CCNP journal, the *Journal of Psychiatry & Neuroscience*, within 6 months after the 2019 CCNP meeting.

_____ 250-word abstract for a paper that could be submitted to the *Journal of Psychiatry & Neuroscience* if I am awarded the prize.

_____ I attest to the accuracy of the information supplied in my application.

__________________________  ________________________
Signature                          Date
## Previous Young Investigator Award Winners

<table>
<thead>
<tr>
<th>Year</th>
<th>Winner(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1987</td>
<td>A. J. Greenshaw</td>
</tr>
<tr>
<td>1988</td>
<td>B. Suranyi-Cadotte</td>
</tr>
<tr>
<td>1989</td>
<td>F. J. Vaccarino</td>
</tr>
<tr>
<td>1990</td>
<td>P. Blier, P.B.S. Clarke</td>
</tr>
<tr>
<td>1991</td>
<td>J. Bradwejn</td>
</tr>
<tr>
<td>1992</td>
<td>M. Martin-Iverson</td>
</tr>
<tr>
<td>1993</td>
<td>R. Joffe</td>
</tr>
<tr>
<td>1994</td>
<td>A. Gratton, J. Poirier</td>
</tr>
<tr>
<td>1995</td>
<td>G. Koren</td>
</tr>
<tr>
<td>1996</td>
<td>G. Robertson</td>
</tr>
<tr>
<td>1997</td>
<td>W. Honer</td>
</tr>
<tr>
<td>1998</td>
<td>J. Nalbantoglu</td>
</tr>
<tr>
<td>1999</td>
<td>S. Kapur</td>
</tr>
<tr>
<td>2000</td>
<td>No award given</td>
</tr>
<tr>
<td>2001</td>
<td>R. Joober</td>
</tr>
<tr>
<td>2002</td>
<td>S. Kar, C.-D. Walker</td>
</tr>
<tr>
<td>2003</td>
<td>G. Turecki</td>
</tr>
<tr>
<td>2004</td>
<td>L.-E. Trudeau</td>
</tr>
<tr>
<td>2005</td>
<td>J. Meyer</td>
</tr>
<tr>
<td>2006</td>
<td>S. Floresco</td>
</tr>
<tr>
<td>2007</td>
<td>M. Lepage</td>
</tr>
<tr>
<td>2008</td>
<td>T. Woodward</td>
</tr>
<tr>
<td>2009</td>
<td>J. Pruessner</td>
</tr>
<tr>
<td>2010</td>
<td>J.-M. Beaulieu, C. Flores</td>
</tr>
<tr>
<td>2011</td>
<td>J. Daskalakis</td>
</tr>
<tr>
<td>2012</td>
<td>G. Gobbi</td>
</tr>
<tr>
<td>2013</td>
<td>L. Booij</td>
</tr>
<tr>
<td>2014</td>
<td>A. Barr</td>
</tr>
<tr>
<td>2015</td>
<td>S. Karama</td>
</tr>
<tr>
<td>2016</td>
<td>M. Chakravarty</td>
</tr>
<tr>
<td>2017</td>
<td>L. Palaniyappan</td>
</tr>
<tr>
<td>2018</td>
<td>I. Boileau, S. Borgland</td>
</tr>
</tbody>
</table>
CCNP 2018 BUSINESS MEETING – THURSDAY, JUNE 28, 2018
12:30 – 13:30 PM Sunroom
UBC Robson Square, Vancouver, British Columbia

ATTENDEES: Drs. Joober (Chair), Leyton, Leri, Mousseau, Baker, Daskalakis, Wong, Srivastava, Goldstein, Honer, Dumont, Mechawar, Booij and Ms. Anderson.

APPROVAL OF THE MINUTES OF THE 2017 CCNP ANNUAL MEETING HELD IN HALIFAX, KINGSTON, ONTARIO (R. Joober):
The minutes of the business meeting were distributed via email prior to the meeting for review.

A motion to accept the minutes was put forward by Dr. Baker and seconded by Dr. Leri. All in favour.

BUSINESS ARISING FROM THE 2017 MINUTES (R. Joober):
Dr. Leri reported that the issue of gender diversity with respect to the CCNP was questioned about two years ago and Dr. Leri did some research into this. There are two components, one being perhaps adding core values of the CCNP to the website and the other being to modify the language in the by-laws and constitution of the CCNP to be gender neutral. Dr. Leri also reviewed other organizations and found an American organization that a section on their website which stated their core values one of which stated they actively support diversity. It was discussed at the council meeting that it may be useful to take these core values and see if we can modify them to fit the CCNP and then post them on our website. If we are committed to diversity, it was noted that the by-laws and constitution have outdated language that’s not gender neutral. These are small modifications that can be done that support diversity but because it is changing the constitution it requires a vote from the active membership for approval. This can be done via an email ballot. Two thirds of the vote of active members who vote is required to make the change. It was asked at this meeting if everyone would be interested in having core values of the CCNP on the website and if everyone is in favour of changing the by-laws and constitution to make it more gender neutral. Everyone at the table was in favour of both. An email ballot will be sent out to the active membership. It was mentioned that 30% of the active membership needs to vote or else it will be void. Dr. Daskalakis asked who all are able to vote and was advised that Fellows and Retired Fellows are able to vote. Dr. Baker had votes on by-laws/constitution in the past and did not have any issues.

REPORT OF THE PRESIDENT (R. Joober):
Please see attached report. Dr. Joober thanked Dr. Barr and the LOC for the great opportunity to come to Vancouver for the meeting and for the great job they have done in organizing the meeting. Traditionally, the CCNP alternates meetings between the East and the West. Next year the meeting will be in Montreal. An LOC has already been formed with Dr. Cecilia Flores being Chair and they have already met twice. They are in the process of finalizing the venue and the meeting will be held either the second or third week of June 2019. The 2020 meeting still needs to be decided. Dr. Joober suggested Toronto and perhaps Drs. Daskalakis and Goldstein being part of the LOC. Dr. Daskalakis mentioned that the CCNP is a smaller organization and perhaps it would be better to have the meeting in a more interesting place that would attract more people. He stated that the meeting is held just before the summer months and maybe people may tack on a vacation after the meeting. Dr. Joober asked Dr. Daskalakis to explore costs of these places, and he and Dr. Goldstein agreed to do this.
A motion was put forward to accept the Report of the President by Dr. Wong and seconded by Dr. Mechawar. All in favour.

REPORT OF THE SECRETARY (D. Mousseau):

*Please see attached report.* Dr. Mousseau reported that it was a relatively slow year. His report is basically dates and events, a calendar/timeline summary of the year.

A motion was put forward to accept the Report of the Secretary by Dr. Joober and seconded by Dr. Dumont. All in favour.

REPORT OF THE TREASURER (T-P. Wong):

*Please see attached report.* Dr. Wong stated that the College's financial status is good. The balance in accounts at the end of 2017 was $170,725.93. The Kingston meeting made over $38,000 profit. The cost of running the College remains similar as in past years but the amount of dues collected is decreasing each year. Dr. Srivastava mentioned that to increase compliance for members to pay their dues several reminders should be sent out. Dr. Wong stated that three reminders were sent out. It is important to increase the membership and the amount of dues collected to help maintain the College. Dr. Mousseau said that there was a rule that if a member hadn't paid dues in over three years that they were removed from the membership list. Dr. Srivastava said that this rule hasn't been held to for several years. Dr. Joober asked Dr. Wong to look at who hasn't paid for the last three years and send them a letter to let them know that they will be removed if dues aren't paid.

Dr. Wong reported that members donated generously this last year to the student fund, over $8,000. He also reported that the Endowment Fund's profile was changed last year into one that had the same risk level but performed better. Dr. Wong stated that the funding from Pfizer Canada for the major awards has enough for only two more years and then a new sponsor will be needed.

A motion was put forward to accept the Report of the Treasurer by Dr. Srivastava and seconded by Dr. Joober. All in favour.

REPORT OF THE JPN (R. Joober):

*Please see attached report.* Dr. Joober reported that the JPN is doing well. It's Impact Factor is 5.16 which puts it 18 out of 142 Psychiatry journals. He thanked all the Associate Editors and reviewers for donating their time.

A motion was put forward to accept the Report of the JPN by Dr. Leyton and seconded by Dr. Wong. All in favour.

REPORT OF THE MEMBERSHIP COMMITTEE (R. Joober for S. Rotzinger):

*Please see attached report.* Dr. Joober reported that there were 13 applicants last year and that less junior members applied than in the past. Dr. Flores sponsored the most new members. Dr. Joober hoped that we can increase membership over the years. The provisional new members were ratified and accepted as full members.

A motion was put forward to accept the Report of the Membership Committee by Dr. Joober and seconded by Dr. Leyton. All in favour.
REPORT OF THE NOMINATING COMMITTEE (R. Joober for J. Foster):
Please see attached report.

REPORT OF THE AWARDS COMMITTEE (R. Joober):
*Please see attached report.* Dr. Joober reported that there were a large number of outstanding nominations this year and it was a challenge to choose recipients. He thanked Pfizer Canada for supporting the awards for five years. Dr. Daskalakis said that it was unusual to not select someone for an award as was the case this year with the ‘Innovations’ Award. He felt it implies that a person is not innovative enough, which could send out a bad message. He asked what is involved in the selection process. Dr. Joober mentioned that there was an issue with the definition of “innovation” and some of the committee members took it very strictly so there was difficulty coming to a decision. He stated that “innovation” needs to be better defined and that more clear criteria is required. He also mentioned that there needs to be some criteria as to why a candidate would not be accepted. Dr. Honer stated that if no candidate is accepted for an award there should be some degree of explanation given to the candidates. Dr. Leri agreed that this makes sense to do. Dr. Leyton mentioned that he is on the Awards Committee and that it was a curious discussion with respect to the Innovations Award and it came down to a very narrow definition of the term and some members were quite strict regarding it. Dr. Joober said that the definition needs to be broadened. Dr. Dumont remarked that this has happened in the past where an award was not given. Dr. Mechawar mentioned that the award needs to be reformulated as to what it recognizes.

Dr. Joober reported that there was discussion in the council meeting to increase the amount of funds given for the travel awards because of the increase in donations this past year. Dr. Wong reported that over $8,000 was received in donations this past year and only $1,500 in travel awards funds is given out each year. It was agreed to allow for $3,000 for the travel awards for 2019.

A motion was put forward to accept the Report of the Awards Committee by Dr. Srivastava and seconded by Dr. Booij.

REPORT OF THE 2018 MEETING IN VANCOUVER, BRITISH COLUMBIA (A. Barr):
*Please see the attached report.* Dr. Barr reported that organizing a meeting is a lot of work but also a lot of fun. He thanked everyone for their help. He reported that they raised around $32,000-$33,000 from sponsors with the possibility of one more company sponsoring. Approximately $32,000 was raised in registration fees. He feels there should be about a $3,000 profit.

A motion was put forward to accept the Report of the 2018 Meeting in Vancouver, British Columbia by Dr. Joober and seconded by Dr. Baker.

Dr. Joober thanked Rachelle Anderson for her help throughout the year. Dr. Ridha said that this was his last year as President and that Dr. Leri is the incoming President and Dr. Daskalakis is the incoming Vice President. Dr. Baker thanked Dr. Joober for his years of service as President.

Meeting adjourned at 1:35 PM.
President's Report 2018
41st Annual Council and Business Meeting, June 27-30, 2018
Submitted by Ridha Joober, MD, PhD

The 41st annual meeting of the CCNP is held in Vancouver under the general theme of "clinical and basic research advancing our understanding of brain function and treatment approaches for psychiatric disorders".

Because of the cost associated with organizing the meeting in locations where accommodations and other logistic aspects are expensive, there were some concerns about holding the meeting in Vancouver. Fortunately, under the leadership of Alasdair Barr and Catharine Winstanley and the support of Dr Bill Honer, the Chair of the Department of Psychiatry at UBC, the decision to hold the meeting in Vancouver was taken, an LOC was formed and started working on organizing the event.

I would like to thank Drs Barr, Honer and all the LOC members for their efforts to ensure an exciting scientific program, with a diversity of themes, combining clinical and basic science research. It is also noticeable that many colleagues from the USA universities are presenting at this meeting. This is a new trend that may be important to develop in the future.

This year, I invited Dr David Goldbloom to give the Presidential Lecture. Dr Goldbloom is a Professor of Psychiatry at the University of Toronto and was the inaugural Physician-in-Chief of the Centre for Addiction and Mental Health in Toronto. He is very well known for his tireless advocacy and work to improve care for patients with mental illness. He has received many prestigious awards, including the appointment as Officer of the Order of Canada. His reflections on the future of Psychiatry will certainly be enlightening.

CCNP Awards:

This year, we received a large number of outstanding nominations in most of the categories. As always, it was challenging to select a winner in some of the categories. I strongly encourage members of the council to actively nominate and encourage their colleagues to nominate scientists for the CCNP awards. The CCNP extends a sincere thank you to Pfizer for their continuous support for the annual awards.

The winners this year are:

Heinz Lehmann Award
Innovations in Neuropsychopharmacology
CCNP Young Investigator Award
CCNP Medal

Dr Alan Evans; PhD (Montreal)
Not awarded
Isabelle Boileau; PhD (Toronto) and Stephanie Borland; PhD (Calgary)
Dr Patricia Boksa; PhD (Montreal)

Because the CCNP meeting is an excellent opportunity for trainees, we are always very proud to continue offering the W.G. Dewhurst Travel Awards ($250). This year, the awards went to:

Tara Delorme (McGill University; Supervisor: Dr. Nicolas Cermakian)
Gabriella Mattina (McMaster University; Supervisor: Dr. Meir Steiner)
Alice Morgunova (McGill University; Supervisor: Dr. Cecilia Flores)
Jose Maria Restrepo (McGill University; Supervisor: Dr. Cecilia Flores)
Lauren Reynolds (McGill University; Supervisor: Dr. Cecilia Flores)
Faranak Vahid-Ansari (University of Ottawa; Supervisor: Dr. Paul Albert)

I would like to congratulate the travel award winners and wish them an excellent meeting. My sincere thank you to the Awards Committee for their hard work to select the winners. This year the members of the committee are: Jeff Meyer (Toronto), Tomas Hajek (Halifax), Paul Fletcher (Toronto), Paul Clarke (Montreal), Marco Leyton (Montreal) and Anne-Noel Samaha (Montreal).

Paul Fletcher and Jeff Meyer have finished their two year tenure on this committee and we welcome Dr. Naguib Mechawar (Basic) and Dr Benjamin Goldstein (Clinical) who have been elected to hold a 2 year term starting June 2018.

Some discussions regarding the definition of innovation in psychopharmacology were raised during the process of adjudication. Some members of the award committee defended a very stringent definition of innovation, that is being the first to discover a new psychopharmacological intervention. Others suggested that by using this stringent criterion it might be difficult to give this award every year, and proposed to consider under innovation significant and early work to make an interventions available to Canadian and advocate for their use. A better definition of this criterion might be needed.

Membership:

The Membership Committee is chaired by Suzanne Rotzinger (Toronto) and includes three members: Paul Albert (Ottawa), and Xin-Min Li (Edmonton).

Recruitment of new members depends on personal contacts and encouraging members of our community to engage in the CCNP. We strongly encourage our active members to invite at least one member to join our organization. This year, 13 new members have joined the CCNP, and I warmly welcome them and am looking forward to their involvement and contribution to our meetings. New membership applications are submitted and circulated to the Membership Committee, and final approval is finalized by the Council and the Membership Committee during the annual meeting.

CCNP Annual Meetings:

The 40th annual meeting was held in Kingston, June 7-8, Ontario. It was a real success both from a scientific and financial points of views.

I would like to thank Dr Roumen Miley, Chair of the LOC and all the members of the LOC for their excellent work. Also, I extend my thanks to the members of the Council who selected the winners for the the Jock Cleghorn Award.

The 41st annual CCNP meeting is being held in Vancouver, June 27-30. We are looking forward to attending an exciting program, with several symposia and presentations, thanks to the efforts of the LOC and various sponsors.

The 42nd meeting will be held in Montreal. An LOC, chaired by Dr Cecilia Flores has been already constituted and met two times. Suggestions for the 43rd meeting will also be welcomed.
Other 2017-2018 Updates:

The question of gender representation was discussed in the 40th CCNP annual meeting. Several propositions have been made, including the creation of a diversity working committee. However, no progress has been made on this question. It is however noticeable that in the last election a good representation of women emerged.

CCNP Officers:

I would like to thank Dr Jane Foster (Past President, Hamilton), Francesco Leri (Vice President, Guelph), Tak-Pan Wong (Treasurer, Montreal), Darrell Mousseau (Secretary, Saskatoon) and all councillors : Shimon Amir (Montreal), Ana Andreazza (Toronto); Linda Booij (Montreal), Simon Ducharme (Montreal), Alina Marin (Kingston), Naguib Mechawar (Montreal), Rajamannar Ramasubbu (Calgary) and Catharine Winstanley (Vancouver).

I would like to welcome:

Dr. Jeff Daskalakis, VP (Clinical)  
Dr. Melissa Perreault, Councillor (Basic)  
Dr. Eric Dumont, Councillor (Basic)  
Dr Cecilia Flores, Councillor (Basic)  
Dr. Isabelle Boileau, Councillor (Clinical)  
Dr. Tomas Hajek, Councillor (Clinical)  
Dr. Abigail Ortiz, Councillor (Clinical)  
Nellie Fotopolous, Junior Councillor  
Dr. Anthony Gifuni, Junior Councillor.

At the last meeting it was noted that many of the councillors do not attend the executive meeting, and it was decided to send a letter reminding them of their engagement to attend the executive meeting and to invite new members to the organization. I have sent a letter to the councillors to this effect.

Jane Foster produced a memo indicating all the steps needed to help the LOC to organize the annual meeting. I have passed this memo to Dr Flores, the Chair of the LOC of the 42nd annual meeting.

Relation with Other Organizations:

1. Our collaboration with the Schizophrenia Society of Canada (SSC) to create a SSC/CCN scholarship in schizophrenia research is ongoing. In this collaboration, the SSC is providing the money to support two scholarships, one for a PhD student and one for an MSc student, each for a period of two years. The CCNP is providing the support to review these applications. The review committee comprises Dr Phil Tibbo (SSC), Dr Tina Montreuil (SSC), Dr Bill Honer (CCNP), Dr Patricia Boks and Dr Lena Palaniyappan (CCNP) and myself (CCNP). In 2017, we received 17 applications and we selected three winners: Franz Veru, PhD candidate (McGill University), T-Jay Anderson MSc candidate (Mount St Vincent University, Halifax) and Tara Delorme (McGill University). The winners are listed on the CCNP website and some of them are presenting at this meeting.
2. European College of Neuropsychopharmacology. The CCNP and ECNP have a longstanding relationship. The most recent memorandum of agreement stipulates that joined symposia can be submitted through the normal channels and, if accepted, they will be advertised as joint symposia.

3. I contacted the ACNP and asked to renew the invitation of CCNP members to attend the ACNP meeting. Unfortunately, this request was turned down, but the ACNP agree to add a link to our annual meeting in their website.

**CCNP Committee Review:**

CCNP committees are important to the smooth functioning of the college. The committees are appointed by the President and approved by the Council. It has been suggested in 2016 that the Clinical Affairs Committee needs review, but no action has been taken. I suggest that we discuss the role of this committee, which will help to select members of this committee.
It was another quiet year for the CCNP and its membership. Here are the highlights (as of May 23, 2018):

➢ Newsletters since last meeting = August 21, 2017; February 6, 2017; April 11, 2017.

➢ A notice for the CCNP 2017 general election was circulated on September 22, 2017, with a deadline for nominations of December 31, 2017. Weekly reminders were circulated throughout November and December. On January 2, 2018, the deadline for nominations for these positions was extended to January 10, 2018. The results of the election (March 26, 2018) are outlined below (Congratulations! and a grateful ‘thank you’ to all those CCNP members who let their name stand):

- Vice-President (Clinical): Jeff Daskalakis
- Treasurer: Tak Pan Wong (by acclamation)
- Secretary: Darrell Mousseau
- Basic Councilor (3): Melissa Perreault, Eric Dumont, and Cecilia Flores
- Clinical Councilor (3): Isabelle Boileau, Tomas Hajek, and Abigail Ortiz
- Junior Councilors: Nellie Fotopolous and Anthony Gifuni
- Awards Committee Basic (1): Naguib Mechawar
- Awards Committee Clinical (1): Benjamin Goldstein (by acclamation)

➢ Announcement for the 41st CCNP meeting in Vancouver and a call for symposia proposals went out concurrently on October 27, 2017 with a deadline of December 31, 2017. Reminders were circulated on December 07, 14, 21, 2017 and a deadline for abstract submission of April 21, 2018 was given. Online registration opened on March 16, 2018, and a call for abstracts was circulated that same day.

➢ Calls for nominations for the CCNP Dewhurst Travel awards (included in the newsletters) and sent out under separate cover on February 2, 2018, and at regular intervals after that. The deadline for applying was March 30, 2018 and decisions were sent out at month’s end.

➢ A call for nominations for the Major CCNP Awards was circulated on September 22, 2017 with a deadline of November 30, 2017, for the letter of nomination, and a deadline of December 31, 2017, for the complete application package. Follow-ups were sent out on September 29, October 23, and November 3, 20, 24, and 28. The Awards Committee received many worthy nominations and ultimately identified the following recipients for each of our Major Awards: Isabelle Boileau (University of Toronto) and Stephanie Borgland (University of Calgary) are co-recipients of the ‘Young Investigator Award’; Alan Evans (McGill University) is the recipient of the ‘Heinz Lehmann Award’; Patricia Bokska (McGill University) is the recipient of the ‘CCNP Medal’. Please note that the Innovations in Neuropsychopharmacology Award was not given out this year. Congratulations to all!

➢ A call for nomination for the 2017 Sam Lal Award was circulated on November 7, 2017.

➢ On January 5, 2018, Ridha Joober contact both the European (ECNP) and American (ACNP) College of Neuropsychopharmacology to circulate the announcement for this year’s meeting
of the CCNP and to invite their respective members to consider providing a symposium to this year's meeting of the CCNP. There was also a request for re-kindling of our past agreements on mutual invitations to the respective meetings. The ECNP did not respond to this request and the ACNP declined the request, based on "a growing attendance and limited space" at their annual meeting(s).

On behalf of the LOC and the CCNP Executive, I welcome all of you to Vancouver for this exciting meeting of the CCNP.

Respectfully submitted,

[Signature]

Darrell D. Mousseau, PhD
Secretary, CCNP (2018)
Canadian College of Neuropsychopharmacology
Treasurer’s Report for 2017

Overview

- Last year’s Annual Meeting was held in Kingston.
  **Total Income: $90,640** (Funds raised: $56,760; Registration: $33,880).
  Pharma contributions: $46,000 (Otsuka Canada Pharmaceutical $10,000, Allergan $5,000,
  Lundbeck $5,000, Ontario Brain Institute $5,000, Pfizer $5,000, Sunovion $5,000, Johnson &
  Johnson $3,000, Lallemand Health Solutions $3,000, Merck $2,000, HLS Therapeutics Inc $1,500,
  Shire $1,500).
  Other contributors: CIHR $5,000, Queen’s University (Queen’s FHS $3,000, Queen’s Research
  Services $1,000), Kingston Psychiatry Partners $1,000, City of Kingston $760.
  **Total Cost of meeting: $52,205.64** (Meeting Operations $46,236.45, Cleghorn Awards $500,
  Innovation Award $1,000, Reimbursements to secretarial support and speakers $4,469.19).
  **Net profit = $38,434.36**

- **Annual cost of running the College is approximately $ 28,855**
  Approx $17,580.48 to run the Edmonton office (Rachelle’s salary $16648.56 + other Edmonton
  expenses, printing, courier, bank charges etc, about $931.92).
  Annual review of financial report: $4,331.25
  Innovation and awards: $1,000 (to cover shortfall from Pfizer money for awards).
  Maintaining the website and registration support, $2172.61; Banking charges, VISA, M/C, Moneris
  fees, $3,534.80, purchasing award plaques $235.70.

- Membership dues for Fellows and affiliate members is: $150. Retired and junior members
  pay $25.
- Membership dues notices and reminders are now sent directly by the website which
  maintains dues database. The notices have a link that members can click to log in to the
  dues payment page. Notices for 2018 dues were sent in Oct 2017, with a reminder in
  December 2017 and April 2018.
- **Dues collected in 2017 = $14,950.**
- Dues collection rate is lower than previous year (compared to $22,000 in 2015 and $17110
  in 2016).
- Members donated generously to **Student bursary fund: $8,640.**
- **Receipts for membership dues are no longer issued as charitable donation; however,
  bursary donations will receive receipts with CRA charity number.**

Summary of CCNP Accounts for 2015, 2016 and 2017:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Petty Cash</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Edmonton acc’t CIBC</td>
<td>793.27</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>BMO ...350 Reserve B</td>
<td>12486.37</td>
<td>13041.31</td>
<td>13656.46</td>
</tr>
<tr>
<td>BMO ...496 Endowment</td>
<td>64255.60</td>
<td>63854.24</td>
<td>63072.52</td>
</tr>
<tr>
<td>BMO ...496 Innovation and Awards (Pfizer)</td>
<td>25079.05</td>
<td>20278.15</td>
<td>15935.86</td>
</tr>
<tr>
<td>BMO ...958 General</td>
<td>41796.51</td>
<td>36680.36</td>
<td>71421.97</td>
</tr>
<tr>
<td>BMO ...482 Dewhurst Awards</td>
<td>3704.34</td>
<td>4280.78</td>
<td>6639.12</td>
</tr>
<tr>
<td>Total</td>
<td>148,115.14</td>
<td>138,134.84</td>
<td>170,725.93</td>
</tr>
</tbody>
</table>
BMO account...350 Reserve B: This is one of our reserve funds. Approx. 31% of the fund is in a GIC. Of the remaining, about 33% is in income funds (bonds) and 36% is in growth funds.

BMO ...496 Endowment: This account has been 90% invested in income funds (mortgages and short term investments) and 10% in growth (Asset Allocation Fund). The performance of income funds has been poor in the last few years. After consulting the financial planner at BMO, the finance committee has decided to invest 90% of the endowment account in Asset Allocation Fund in October 2017. Sixty percent of the income from this fund is transferred to the Awards account to help pay the Dewhurst Travel Awards for trainees; the remaining 40% is reinvested into the endowment fund.

BMO...496 Innovation and Awards (Pfizer): $25,000 from Pfizer was received in Feb 2015 to fund Innovation, Lehmann and Young Investigator awards for the next 5 years (2016-2020; $5,000 per year). The money was invested as a separate portfolio (Select Class Income Portfolio) within the Endowment account #496 to generate annual income to be redeemed every year for awards. Asset allocations in the fund are 60% Bond, 30% Stock and cash and other. The first redemption of $5,000 was made in May 2017 to fund the awards (Note that the balance of award money, i.e., $1,000 will come from the General fund 958).

BMO ...General 958: This is the general checking bank account for operating funds kept in BMO Hamilton (but operated from Montreal).

BMO ...482: This is a savings account used to pay Dewhurst travel awards. The account comprises income from Endowment fund 496 and contributions from members. Members’ 2017 contribution of $8,640 was deposited in the General account #958, and therefore is not reflected in the balance of account #482 shown in the Table above.

Summary

Due to the very successful fund raising for the Kingston meeting, the financial state of the college remains good. I also like to thank the generous donations made by our members to support the student bursary fund. The declining membership dues collected in the last couple years still post a challenge for balancing the cost for the annual operation of CCNP, especially when annual meetings could not make profits in future.

Submitted by Tak Pan Wong on Thursday, May 24, 2018.
Journal of Psychiatry and Neuroscieince (JPN)

Report to the Canadian College of Neuropsychopharmacology, May 2018

JPN publishes papers at the intersection of psychiatry and neuroscience, that investigate the mechanisms involved in the etiology and treatment of psychiatric disorders. Following discussions among the Editorial Board, it was decided that the journal will now broaden its scope to also consider high quality clinical papers addressing psychiatric disorders, especially those with a mechanistic component.

The 2-year impact factor for JPN for 2016 was 5.16, putting it at #18 out of 142 Psychiatry journals and #38 out of 258 Neuroscience journals. JPN’s impact factor remains higher than that of some of the journal’s competitors including Int J Neuropsychopharm (4.7, official journal of CiNP), Translational Psychiatry (4.7), Eur Neuropsychopharm (4.2, official journal of ECNP), J Psychiatr Res (4.1), J Psychopharm (4.1, official journal of BAP), Schizophrenia Res (4.0), Psychopharmacology (3.3).

For the year ending May 2018, JPN received 207 submissions (research papers, reviews, commentaries) and our acceptance rate was 20%. See Table 1 for comparisons to previous years. For the past year, JPN published a total of 36 research papers (average 6 papers/issue), as well as 6 Editorials and 7 Psychopharmacology for the Clinician articles. Papers originating from 22 different countries were published in JPN, with 36% of published papers coming from labs in Canada.

We welcome high quality submissions of any type appropriate to the journal. We are in particular need of articles for our popular Psychopharmacology for the Clinician (PFC) feature, and welcome submissions from you or a colleague. (PFC columns are listed on PubMed, and are usually downloaded several hundred times in the first few weeks after publication and more thereafter.) Please note that the format of PFC columns is fairly specific, a description of which can be found at http://jpn.ca/instructions-for-authors/ .

We would like to thank our Associate Editors for donating their time to write thought-provoking editorials, review Psychopharmacology columns and editorials, and contribute to policy discussion: Paul Albert, Martin Alda, Hymie Anisman, Yvon Lapierre (Editor Emeritus), Marco Leyton and Glenda MacQueen, and to our hard-working Statistical Associate Editors, Aurelie Labbe and Norbert Schmitz. We would also like to express our appreciation to all of the many conscientious reviewers who have donated their time and expertise to reviewing papers for JPN, gratis.

Special thanks to Wendy Carroll, now Managing Editor of the CMAJ Group, for her unfailing support and work for the journal and to Holly Clark, Editorial Co-ordinator, at the publication end of JPN.

Respectfully submitted,

Patricia Boksa  
Patricia.boksa@mcgill.ca

Ridha Joobier  
ridha.joobier@douglas.mcgill.ca

Co-Editors in Chief
### Table 1. JPN Stats

<table>
<thead>
<tr>
<th>Year (ending May)</th>
<th># MS Accepted / # MS Submitted</th>
<th>Acceptance Rate</th>
<th>% submitted from Canada Accepted</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017-2018</td>
<td>41 / 207</td>
<td>19.8 %</td>
<td>75%</td>
</tr>
<tr>
<td>2016-2017</td>
<td>39 / 236</td>
<td>16.5 %</td>
<td>41%</td>
</tr>
<tr>
<td>2015-2016</td>
<td>46 / 286</td>
<td>16.1 %</td>
<td>25%</td>
</tr>
<tr>
<td>2014-2015</td>
<td>59 / 411</td>
<td>14.3 %</td>
<td>27%</td>
</tr>
<tr>
<td>2013-2014</td>
<td>54 / 311</td>
<td>17.4 %</td>
<td>41%</td>
</tr>
<tr>
<td>2012-2013</td>
<td>61 / 243</td>
<td>25.1 %</td>
<td>52%</td>
</tr>
<tr>
<td>2011-2012</td>
<td>49 / 247</td>
<td>19.8 %</td>
<td>41%</td>
</tr>
<tr>
<td>2010-2011</td>
<td>50 / 148</td>
<td>36.2 %</td>
<td>38%</td>
</tr>
<tr>
<td>2009-2010</td>
<td>51 / 204</td>
<td>25.0 %</td>
<td>43%</td>
</tr>
<tr>
<td>2008-2009</td>
<td>37 / 182</td>
<td>20.3 %</td>
<td>38%</td>
</tr>
</tbody>
</table>
CCNP 2018  
Vancouver, British Columbia  
Membership Committee Report  
Submitted by: Susan Rotzinger

• As of May 28, 2018, we have received 13 applications for new memberships: 5 at the level of Fellow (up from 4 last year) and only 8 Junior applications (down from 20 the previous year). No change of status applications were received. All have received provisional approval from the membership committee.

• Sponsorships of new members came from across the membership, with Dr. Flores sponsoring the most applicants (3) followed by Drs. Leri and Frey with 2 each.

PROVISIONAL NEW CCNP MEMBERS FOR 2017-2018

FELLOWS:

BOSSERT, Jennifer, PhD
Staff Scientist
Department of Behavioral Neuroscience
IRP/NIDA/NIH/DHHS
251 Bayview Blvd., Suite 200
Baltimore, Maryland USA 21239
Tel. (443) 740-2724
Fax (443) 740-2827
Email: Jennifer.bosser@nih.gov or get_hip@hotmail.com
Sponsor: Dr. F. Leri

BOUSMAN, Chad, MPH, PhD
Assistant Professor
Department of Medical Genetics
University of Calgary
2500 University Drive NW, CDC 395
Calgary, AB T3B 2X9
Tel. (403) 441-8409
Email: chad.bousman@ucalgary.ca
Sponsor: Dr. D. Mueller

BOWIE, Christopher, PhD
Professor
Department of Psychology
Queen’s University
62 Arch Street
Kingston, ON K7L 3N6
Email: bowiec@queensu.ca
Sponsor: Dr. M. Lepage

LORDANOVA, Mihaela, PhD
Assistant Professor
Department of Psychology
Concordia University
7141 Sherbrooke St. West, SP 244
Montreal, QC
Tel. (514) 848-2424
Email: mihaela.lordanova@concordia.ca
Sponsor: Dr. C. Flores

MURRAY, Jennifer, PhD
Assistant Professor
Department of Psychology
University of Guelph
50 Stone Road East
MacKinnon Extension
Guelph, ON N1G 2W1
Tel. (519) 824-4120 Ext. 56330
Email: jmurr@uoguelph.ca
Sponsor: Dr. F. Leri

JUNIOR MEMBERS:
CARDOSO, Tatiane, PhD
Postdoctoral Research Fellow
Department of Psychiatry & Behavioral Neurosciences
McMaster University
100 West 5th Street, Suite G110
Hamilton, ON L8N 3K7
Email: deazevet@mcmaster.ca
Sponsor: Dr. B. Frey

DELORME, Tara, BSc.
Graduate Student
Department of Psychiatry
McGill University
6875 Boulevard LaSalle
Verdun, QC H4H 1R3
Tel. (438) 274-4158
Email: todelorme@hotmail.com or tara.delorme@mail.mcgill.ca
Sponsor: Dr. L. Srivastava

DEMPSTER, Kara, MD
Resident, Master of Neuroscience Candidate
Department of Psychiatry
London Health Sciences Centre
3-1850 Beaverbrook Ave.
London, ON N6H 0G7
Tel. (226) 234-2119
Email: kara.dempster@gmail.com
Sponsor: Dr. L. Palaniyappan

GIFUNI, Anthony, MD, MSc, FRCPC
PGY-6 Resident
Department of Psychiatry
McGill University
669 Brault St.
Verdun, QC H4H 2B3
Tel. (514) 999-6069
Email: Anthony.gifuni@gmail.com or Anthony.gifuni@mail.mcgill.ca
Sponsor: Dr. S. Karama

MORGUNOVA, Alice, BA
Graduate Student
IPN Department, McGill University
Psychiatry, 6875 Boulevard LaSalle
Verdun, QC H4H 1R3
Tel. (503) 554-8656
Email: alice.morgunova@mail.mcgill.ca
Sponsor: Dr. C. Flores

OH, Gary, BSc. Hon., MD
Medical Student
#210, 4901 South Drexel Blvd.
Chicago, IL USA 60615
Tel. (773) 526-1436
Email: gary.cs.oh@gmail.com
Sponsor: Dr. G. Baker

PFAFFENSELLER, Bianca, BSc, MSc, PhD
Postdoctoral Research Fellow
Department of Psychiatry & Behavioral Neurosciences
McMaster University
100 West 5th Street, Suite G116
Hamilton, ON L8N 3K7
Tel. (365) 888-5777
Email: pfaffenb@mcmaster.ca or Bianca.pfaeffenseller@gmail.com
Sponsor: Dr. B. Frey

RESTREPO, Mr. Jose Maria, MSc.
Department of Neuroscience, McGill University
Apt. A, 460 rue Abelard
Quebec, QC H3E 1B5
Tel. (514) 298-5188
Email: jose.restrepo2@mail.mcgill.ca
Sponsor: Dr. C. Flores

CHANGE IN STATUS:

AFFILIATE MEMBERS:
Members:

Jane Foster – Chair (Hamilton)
Daniel Mueller (Toronto)
Darrell Mousseau (Saskatoon)
George Robertson (Halifax)
Anne-Noel Samaha (Montreal)
Catharine Winstanley (Vancouver)

CCNP 2018 Election

A call for CCNP Council and Awards Committee members was circulated in October 2017. The deadline for nominations for the 2017 CCNP election was December 31, 2017 and the ballot was circulated to the membership in January 2018. The election ballots were tabulated and confirmed. The following individuals were elected and will commence their two-year position after the June 2018 Annual Meeting.

Awards Committee – Clinical (1):
Dr. Benjamin Goldstein (by acclamation)

Awards Committee – Basic (1):
Dr. Naguib Mechawar

Basic Councillor (3):
Dr. Melissa Perreault
Dr. Eric Dumont
Dr. Cecilia Flores

Clinical Councillor (3):
Dr. Isabelle Boileau
Dr. Tomas Hajek
Dr. Abigail Oritz

Secretary:
Dr. Darrell Mousseau

Treasurer:
Dr. Tak Pan Wong (by acclamation)

VP (Clinical):
Dr. Jeff Daskalakis
Report of the 2018 Meeting in Vancouver, British Columbia

The 41st Annual Conference of the Canadian College of Neuropsychopharmacology will be held at the UBC Robson Square conference center, located in the heart of beautiful downtown Vancouver. Previous CCNP meetings have been held on UBC campus and this year we decided to hold the conference downtown to broaden the appeal of the venue. The conference will take place over 3 full days (June 28-30th, 2018). We have scheduled 8 symposia presentations over the course of the conference. These will include talks on current issues including a report by Dr Richard Huntsman on his clinical trial of cannabidiol for pediatric epilepsy, as well as a symposium on neurostimulation by Drs Vila-Rodriguez and Daskalakis who reported their findings in *Lancet* last month. The Presidential Lecture will be given by Dr Davis Goldbloom, Senior Medical Advisor for the Centre for Addiction and Mental Health and Professor of Psychiatry at the University of Toronto. The program will also consist of 3 award lectures (2 Young Investigator Award lectures and the Heinz Lehmann Award Lecture) as well as Next Generation presentations which will focus on the topical issue of opioid abuse. The poster sessions have been split to take place over a 2-day format.

After the meeting, the abstracts of the oral and poster presentations will be available to the Journal of Psychiatry and Neuroscience, the official journal of the college. The entire program is paper-free and will be available for download as a PDF.

The conference website was maintained through CCNP. The Website managed registration and abstract submissions. The CCNP Gala Dinner will be held in the West Ocean Foyer at the Vancouver Convention Centre, a ten minute walk from the main conference center.

The LOC has currently raised $18,000 from non-registration sources to offset the cost of the meeting. Revenue from registration is currently at $25,870, although we expect more people to register locally in the next month. Projected costs at this time are approximately $39,300. Based on the projected costs for the venue and other expenses, we are hoping to make a small profit but cannot confirm the amount until after the conference expenses and revenue have been reconciled.

Sponsors who have confirmed support:
- Janssen - $5,000
- Pfizer - $5,000
- Otsuka - $4,000
- Sunovion - $5,000
- HLS Therapeutics - $1,500

Sponsors who have expressed interest but yet to confirm support:
- Lundbeck
- Shire
- CanniMed
- Allergan
- UBC Faculty of Medicine
- UBC Centre for Brain Health
- BC Children's Hospital